Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML-Reference-Cited by-同舟云学术

Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML

Published:2022-12 Issue: Volume:27 Page:315-332
ISSN:2372-7705
Container-title:Molecular Therapy - Oncolytics
language:en
Short-container-title:Molecular Therapy - Oncolytics

Author:

Fujii Shin-ichiro^ORCID,Kawamata Toyotaka,Shimizu Kanako,Nakabayashi Jun,Yamasaki Satoru,Iyoda Tomonori,Shinga Jun,Nakazato Hiroshi,Sanpei An,Kawamura Masami,Ueda Shogo,Dörrie Jan,Mojsov Svetlana,Dhodapkar Madhav V.,Hidaka Michihiro,Nojima Masanori,Nagamura Fumitaka,Yoshida Shigemi,Goto Toshio,Tojo Arinobu

Publisher

Elsevier BV

Subject

Pharmacology (medical),Cancer Research,Oncology,Molecular Medicine

Reference51 articles.

1. Therapeutic cancer vaccines: are we there yet?;Klebanoff;Immunol. Rev.,2011

2. Vaccine therapy in hematologic malignancies;Avigan;Blood,2018

3. Dendritic cells in vivo: a key target for a new vaccine science;Steinman;Immunity,2008

4. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205;Dhodapkar;Sci. Transl. Med.,2014

5. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy;Kranz;Nature,2016

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network-Constrained Eigen-Single-Cell Profile Estimation for Uncovering Crucial Immunogene Regulatory Systems in Human Bone Marrow;Journal of Computational Biology;2024-09-06

2. Tumor epitope spreading by a novel multivalent therapeutic cellular vaccine targeting cancer antigens to invariant NKT-triggered dendritic cells in situ;Frontiers in Immunology;2024-02-01

3. Vaccinating against cancer: getting to prime time;Journal for ImmunoTherapy of Cancer;2023-06

4. Maintenance therapy in acute myeloid leukemia: advances and controversies;Haematologica;2023-05-04

5. Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide;Cancer Immunology, Immunotherapy;2023-04-24